Opinion|Videos|June 28, 2024
Analyzing the MARIPOSA-2 Trial Data’s Impact on Clinical Practice
Cara Chang, PharmD, BCOP, provides a comprehensive analysis of the MARIPOSA-2 trial, evaluating the various study arms and interpreting the practice-changing data presented.
Advertisement
Episodes in this series
- The
MARIPOSA-2 trial, a recent publication from January, assessed patients with Ex19del or Ex21 L858R mutations who had progressed on osimertinib. It compared three treatment arms: amivantamab plus lazertinib plus chemotherapy, amivantamab plus chemotherapy (without lazertinib), and chemotherapy alone. What are the significant findings of this study, and what are the key insights that could influence clinical practice? - When it comes to patients with S768I, L861Q, and/or G719X mutations, how does their treatment approach differ from (or is similar to) those observed in the FLAURA2 and MARIPOSA / MARIPOSA-2 studies?
Advertisement
Related to this article
This update came with no changes to the safety sections of labeling, with no new signals identified with longer follow-up.
The update shortens required observation to 6 to 8 hours from 22 to 24, easing tarlatamab administration in community settings for ES-SCLC.
A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.
Eight-year phase 3 ADAURA trial data show adjuvant osimertinib boosts survival in patients with resected EGFR-mutant NSCLC.
Phase 3 HARMONi-2 interim analysis shows first bispecific PD-1/VEGF antibody outperforming standard immunotherapy in first-line NSCLC.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
The FDA expanded the accelerated approval of sevabertinib to include treatment-naive adults with locally advanced or metastatic nonsquamous NSCLC harboring HER2 tyrosine kinase domain-activating mutations.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
2
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
3
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
4
Beyond Cost Avoidance: Advancing Unit-Level Pharmaceutical Economics in Health Systems
5